Teva to Present at the Canaccord Genuity 33rd Annual Growth Conference

  Teva to Present at the Canaccord Genuity 33rd Annual Growth Conference

Canaccord Genuity Global Growth Conference 2013

Business Wire

JERUSALEM -- August 13, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio
webcast at the Canaccord Genuity 33^rd Annual Growth Conference in Boston,
Massachusetts. Dr. Jeremy M. Levin, President & CEO, will present on
Wednesday, August 14, 2013 at 9:30 AM ET.

What:    Teva Presentation at the Canaccord Genuity 33^rd Annual Growth
           Conference
           
Who:       Dr. Jeremy M. Levin, President & CEO, Teva Pharmaceutical
           Industries Ltd.
           
When:      Wednesday, August 14, 2013
           
Where:     www.tevapharm.com
           
           Live over the Internet – log on to the Web at the address above and
How:       register for the event (approximately 10 minutes before). An
           archive of the webcast will be available on Teva’s website.
           

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Contact:

Teva Pharmaceutical Industries Ltd.
IR Contacts:
United States
Kevin C. Mannix, 215-591-8912
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR Contacts:
Israel
Iris Beck Codner, 972 (3) 926-7246
or
United States
Denise Bradley, 215-591-8974